Summary
23.89 -0.30(-1.22%)11/19/2024
Denali Therapeutics Inc (DNLI)
DNLI reported last earnings on 2024-11-06 after the market. An EPS of $-0.63 was observed compared to an estimated EPS of $-0.6, resulting in a surprise value of $-0.03. A revenue of $0 million was observed compared to an estimated revenue of $12 million, resulting in a surprise value of $-12 Million.
Denali Therapeutics Inc (DNLI)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -1.22 | -23.36 | -12.43 | 1.71 | 21.33 | 26.89 | 59.67 | 13.52 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
Earnings
Fundamental Ratings
| Category | Rating |
| Main Rating | C |
| Recommended Rating | Sell |
| DCF | Strong Sell |
| ROE | Strong Sell |
| ROA | Strong Sell |
| Debt/Equity | Buy |
| P/E | Strong Sell |
| P/B | Sell |
| Trading Data | ||
| Close | 23.89 | |
| Open | 24.00 | |
| High | 24.00 | |
| Low | 23.53 | |
| Volume | 30,079 | |
| Change | -0.30 | |
| Change % | -1.22 | |
| Avg Volume (20 Days) | 794,562 | |
| Volume/Avg Volume (20 Days) Ratio | 0.04 | |
| 52 Week Range | 14.58 - 33.32 | |
| Price vs 52 Week High | -28.32% | |
| Price vs 52 Week Low | 63.82% | |
| Range | -2.87 | |
| Gap Up/Down | -3.38 | |
Fundamentals | ||
| Market Capitalization (Mln) | 3,785 | |
| EBIDTA | 34,068,000 | |
| PE Ratio | 191.5678 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 89.00 | |
| Book Value | 8.2970 | |
| Earnings Per Share | 0.2360 | |
| EPS Estimate Current Quarter | -0.4700 | |
| EPS Estimate Next Quarter | -0.3800 | |
| EPS Estimate Current Year | -2.1800 | |
| EPS Estimate Next Year | -2.4100 | |
| Diluted EPS (TTM) | 0.2360 | |
| Revenues | ||
| Profit Marging | 0.0838 | |
| Operating Marging (TTM) | 0.0721 | |
| Return on asset (TTM) | 0.0126 | |
| Return on equity (TTM) | 0.0312 | |
| Revenue TTM | 352,961,984 | |
| Revenue per share TTM | 2.9160 | |
| Quarterly Revenue Growth (YOY) | -0.4370 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 123,044,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 191.5678 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 5.2251 | |
| Revenue Enterprise Value | 12.2260 | |
| EBITDA Enterprise Value | 126.6680 | |
| Shares | ||
| Shares Outstanding | 122,126,000 | |
| Shares Float | 84,640,355 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 16.61 | |
| Institutions (%) | 79.53 | |
11/16 08:56 EST - seekingalpha.com
Denali Has A Neurodegenerative Edge Despite Market Skepticism
Denali Therapeutics' unique blood-brain barrier technology and strategic partnerships offer a significant edge in the challenging neurodegenerative disease landscape. The company's strong cash position and disciplined financial strategy support its ambitious R&D and commercialization efforts...
Denali Has A Neurodegenerative Edge Despite Market Skepticism
Denali Therapeutics' unique blood-brain barrier technology and strategic partnerships offer a significant edge in the challenging neurodegenerative disease landscape. The company's strong cash position and disciplined financial strategy support its ambitious R&D and commercialization efforts...
11/08 11:10 EST - zacks.com
Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging
DNLI reports a wider-than-expected loss in the third quarter of 2024. Nonetheless, the pipeline progress has been encouraging.
Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging
DNLI reports a wider-than-expected loss in the third quarter of 2024. Nonetheless, the pipeline progress has been encouraging.
11/06 16:01 EST - globenewswire.com
Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the third quarter ended September 30, 2024, and provided business highlights.
Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the third quarter ended September 30, 2024, and provided business highlights.
10/29 11:06 EST - zacks.com
Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Denali Therapeutics (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Denali Therapeutics (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
09/16 12:26 EST - zacks.com
Strength Seen in Denali Therapeutics (DNLI): Can Its 10.1% Jump Turn into More Strength?
Denali Therapeutics (DNLI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Strength Seen in Denali Therapeutics (DNLI): Can Its 10.1% Jump Turn into More Strength?
Denali Therapeutics (DNLI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
09/04 12:41 EST - zacks.com
Denali Plans to File for Accelerated Approval of Hunter Syndrome Drug
DNLI's recent meeting with the FDA was successful and provides the path to file for accelerated approval of tividenofusp alfa for the treatment of MPS II and its subsequent conversion to full approval.
Denali Plans to File for Accelerated Approval of Hunter Syndrome Drug
DNLI's recent meeting with the FDA was successful and provides the path to file for accelerated approval of tividenofusp alfa for the treatment of MPS II and its subsequent conversion to full approval.
09/03 08:00 EST - globenewswire.com
Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced the outcome of a recent successful meeting with the Center for Drug Evaluation and Research (CDER) division of the U.S. Food and Drug Administration (FDA) providing a path to...
Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced the outcome of a recent successful meeting with the Center for Drug Evaluation and Research (CDER) division of the U.S. Food and Drug Administration (FDA) providing a path to...
08/19 22:55 EST - seekingalpha.com
Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology
Denali Therapeutics' proprietary Transport Vehicle technology enables drug delivery across the blood-brain barrier, targeting neurodegenerative diseases. DNL310, targeting MPS II, and DNL343 for ALS are key drug candidates with potential, though competition is significant. The company's $500...
Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology
Denali Therapeutics' proprietary Transport Vehicle technology enables drug delivery across the blood-brain barrier, targeting neurodegenerative diseases. DNL310, targeting MPS II, and DNL343 for ALS are key drug candidates with potential, though competition is significant. The company's $500...
08/14 14:00 EST - globenewswire.com
Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration
SOUTH SAN FRANCISCO, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative and lysosomal storage...
Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration
SOUTH SAN FRANCISCO, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative and lysosomal storage...
08/06 10:55 EST - zacks.com
Wall Street Analysts Believe Denali Therapeutics (DNLI) Could Rally 79.62%: Here's is How to Trade
The consensus price target hints at a 79.6% upside potential for Denali Therapeutics (DNLI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Believe Denali Therapeutics (DNLI) Could Rally 79.62%: Here's is How to Trade
The consensus price target hints at a 79.6% upside potential for Denali Therapeutics (DNLI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
08/01 06:45 EST - globenewswire.com
Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal...
Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal...
07/23 07:16 EST - zacks.com
Denali Therapeutics (DNLI) Stock Jumps 9.7%: Will It Continue to Soar?
Denali Therapeutics (DNLI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Denali Therapeutics (DNLI) Stock Jumps 9.7%: Will It Continue to Soar?
Denali Therapeutics (DNLI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
07/08 19:09 EST - investorplace.com
3 Longevity Stocks to Buy for Anti-Aging Breakthroughs
The United States population is aging faster than ever, attracting interest in longevity stocks. By 2030, one in five Americans will be a senior citizen, up from one in twenty 100 years ago.
3 Longevity Stocks to Buy for Anti-Aging Breakthroughs
The United States population is aging faster than ever, attracting interest in longevity stocks. By 2030, one in five Americans will be a senior citizen, up from one in twenty 100 years ago.
06/28 09:40 EST - zacks.com
Denali (DNLI) Outperforms Industry in 3 Months: Here's Why
Denali (DNLI) gains 11.9% in three months on positive updates on its candidates.
Denali (DNLI) Outperforms Industry in 3 Months: Here's Why
Denali (DNLI) gains 11.9% in three months on positive updates on its candidates.
06/24 10:10 EST - zacks.com
Denali Therapeutics (DNLI) Moves 5.8% Higher: Will This Strength Last?
Denali Therapeutics (DNLI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Denali Therapeutics (DNLI) Moves 5.8% Higher: Will This Strength Last?
Denali Therapeutics (DNLI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
06/06 12:36 EST - zacks.com
Why Is Denali Therapeutics (DNLI) Up 15.6% Since Last Earnings Report?
Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock?
Why Is Denali Therapeutics (DNLI) Up 15.6% Since Last Earnings Report?
Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock?
06/04 14:21 EST - zacks.com
Denali's (DNLI) Candidate Selected for FDA's START Pilot Program
Denali's (DNLI) DNL126, an investigational enzyme replacement therapy, gets selected for the START Pilot Program, intended to accelerate the development of rare disease therapies.
Denali's (DNLI) Candidate Selected for FDA's START Pilot Program
Denali's (DNLI) DNL126, an investigational enzyme replacement therapy, gets selected for the START Pilot Program, intended to accelerate the development of rare disease therapies.
06/03 08:00 EST - globenewswire.com
Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies
SOUTH SAN FRANCISCO, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative and lysosomal storage...
Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies
SOUTH SAN FRANCISCO, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative and lysosomal storage...
05/13 12:30 EST - seekingalpha.com
Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data
Denali Therapeutics Inc.'s DNL-310 is currently being explored in an ongoing phase 2/3 COMPASS study for treatment of patients with MPS II; Enrollment completion expected in 2024. Denali is in talks with CDER division of FDA to seek for Accelerated Approval pathway for DNL-310 for the treatment of...
Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data
Denali Therapeutics Inc.'s DNL-310 is currently being explored in an ongoing phase 2/3 COMPASS study for treatment of patients with MPS II; Enrollment completion expected in 2024. Denali is in talks with CDER division of FDA to seek for Accelerated Approval pathway for DNL-310 for the treatment of...
05/08 09:21 EST - zacks.com
Denali (DNLI) Q1 Earnings Miss, Pipeline Progress in Focus
Denali (DNLI) Q1 loss narrows year over year due to lower expenses despite nil revenues.
Denali (DNLI) Q1 Earnings Miss, Pipeline Progress in Focus
Denali (DNLI) Q1 loss narrows year over year due to lower expenses despite nil revenues.